Cyclo Therapeutics (CYTH)
(Delayed Data from NSDQ)
$1.08 USD
-0.02 (-1.82%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.11 +0.03 (2.78%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CYTH 1.08 -0.02(-1.82%)
Will CYTH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CYTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for CYTH
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer?s Disease from European Patent Office
Cyclo Therapeutics granted patent by European Patent Office
One new option listing and eighteen option delistings on July 22nd
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results